NETVAL – EXPLOITING INNOVATION IN HEALTHCARE

LECCE – SUMMER SCHOOL July 12th 2017

Gianni D’Errico

European Funding Officer
In Lombardy, in the last 3 years 700 M€ have been invested in Clinical Trials (3rd market in Europe).

50% of clinical trials for drug development in Italy are carried out in Lombardy.

The pharmaceutical production is worth 30 Billion € per Year.

3 main industrial sectors: Pharma, Biotech and Medtech are the main sectors of the Life Science in Lombardy.
WHO WE ARE

MISSION: PROMOTE AND SUPPORT EXCELLENT BIOMEDICAL RESEARCH WITHIN THE TERRITORY

DIRECTOR GENERAL: Dr. Marina Gerini
- Grant office
- Scientific office
- European funding office
- Public affairs
- Administration
- Secretary

CHAIRMAN: Dr. Cristina Cagnazzi
Director: Dr. Luigi Gianola
Director: Dr. Luca Degani

STAFF

FRRB

2017

Scientific Committee:
- Dr. Gianvito Martino (President) Hsr
- Dr. Silvia Priori (IRCCS Maugeri)
- Dr. Andrea Biondi (Fondazione MBBM)
- Dr. Fabrizio Tagliavini (IRCCS Besta)
- Dr. P. Giuseppe Pelicci (IEO)
- Dr. Sergio Abrignani (INGM)
- Dr. Silvano Sozzani (Università Brescia)

2011

LOMBARDY REGION
Support and implement the health care research policy in Lombardy

Funding Biomedical research projects

Boost European activities and network

Funding researcher’s careers

IP and cluster cooperation
Since 2015, the Foundation supports Lombardy Region in the strategic development of tools to implement Personalized Medicine approaches, identified as a driver in the Biomedical Research evolution.

**Personalized Medicine**

Personalized Medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.

<table>
<thead>
<tr>
<th>SPLITTER approach</th>
<th>VS</th>
<th>LUMPER approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>Every difference makes the individual unique</td>
<td></td>
<td>Similar therapies for similar pathologies, independently from the patient</td>
</tr>
</tbody>
</table>

To this aim, the Foundation has developed two main actions:

1. Funding innovative Biomedical Research projects, which could provide concrete advancements in the field of Personalized Medicine in Lombardy
2. Empower Lombardy Region as the first region involved in Personalized Medicine at European level
PUBLIC CONSULTATION IN LOMBARDY AND EU

Type of Market Barriers identified in Lombardy

<table>
<thead>
<tr>
<th>Type</th>
<th>Tecnologica</th>
<th>Economica</th>
<th>Regolatoria</th>
<th>Legislativa</th>
<th>Commercial</th>
<th>Culturale</th>
<th>Formativa</th>
</tr>
</thead>
<tbody>
<tr>
<td>M</td>
<td>10</td>
<td>13</td>
<td>21</td>
<td>19</td>
<td>6</td>
<td>21</td>
<td>10</td>
</tr>
<tr>
<td>R</td>
<td>14</td>
<td>29</td>
<td>19</td>
<td>13</td>
<td>3</td>
<td>15</td>
<td>7</td>
</tr>
<tr>
<td>C</td>
<td>17</td>
<td>25</td>
<td>16</td>
<td>7</td>
<td>2</td>
<td>23</td>
<td>10</td>
</tr>
<tr>
<td>A</td>
<td>7</td>
<td>19</td>
<td>20</td>
<td>11</td>
<td>4</td>
<td>20</td>
<td>19</td>
</tr>
</tbody>
</table>

FEBRUARY – MAY 2017

EC PUBLIC CONSULTATION ON ACCESS AND MANAGEMENT OF PERSONAL HEALTH DATA
JULY 20TH – OCTOBER 12TH

Introduction

The purpose of this consultation is to define the need and scope of policy measures that will promote digital innovation in improving people’s health, and address systemic challenges to health and care systems. Those measures must be aligned with legislation on the protection of personal data, patient rights and electronic identification. The consultation collects views on:

- Cross-border access to and management of personal health data;
- A joint European exploitation of resources (digital infrastructure, data capacity), to accelerate research and to advance prevention, treatment and personalised medicine;
- Measures for widespread uptake of digital innovation, supporting citizen feedback and interaction between patients and health care providers.
FUNDING INNOVATIVE BIOMEDICAL RESEARCH PROJECTS - 2015

€ 3,220,980  
CYTOMEGALOVIRUS INFECTIONS

€ 3,964,800  
RHEUMATOID ARTHRITIS

€ 3,855,478  
AMIOTROFIC LATERAL SCLEROSIS

€ 4,166,400  
HEMATOLOGIC MALIGNACIES
FUNDING INNOVATIVE BIOMEDICAL RESEARCH PROJECTS - 2017

€ 1.200.000
EXPLORATORY GRANT

€ 3.964.800
SPECIAL PROJECT

€ 20.000.000
COLLABORATIVE PROJECTS

€ 1.500.000
FELLOWSHIP
FRRB is willing to lead the European Network of Regions in Personalised Medicine.

FRRB is partner in the project for the ERA-NET on personalised medicine.

In March 2017 the Interregional Action Plan is released.

Our European Strategy on Personalised Medicine

The European Strategy on Personalised Medicine

Strategic Research and Innovation Agenda on Personalised Medicine

FRRB (and Lombardy Region) is member of the Executive Committee.

The Interregional Action Plan is released in March 2017.
EUROPEAN PROJECTS & INITIATIVES

International Consortium for Personalized Medicine **IC-PERMED**
*Action Plan implementation phase*

- 26-27 giugno 2017
- International Workshop IC PERMED in MILAN

ERANET Translational Cancer Research **TRANSCAN 2**
The Foundation funds ERA-NET projects on Translational Cancer research
2016: 1 Mln € funded (Non invasive methods for early diagnosis)
2017: Topic to be defined

**ERA-PERMED**
The Foundation is part of the ERA-NET secretariat on Personalized Medicine and is in charge of monitoring the results and the impacts of the funded transnational project.
<table>
<thead>
<tr>
<th>Country</th>
<th>Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Federal Ministry of Science, Research and Economy</td>
</tr>
<tr>
<td>Austria</td>
<td>Federal Ministry of Health and Women's Affairs</td>
</tr>
<tr>
<td>Canada</td>
<td>Canadian Institutes of Health Research</td>
</tr>
<tr>
<td>Canada (Region)</td>
<td>Genome British Columbia</td>
</tr>
<tr>
<td>Republic of Croatia</td>
<td>Ministry of Science and Education of the Republic Croatia</td>
</tr>
<tr>
<td>Cyprus</td>
<td>Research Promotion Foundation</td>
</tr>
<tr>
<td>Czech Republic</td>
<td>Ministry of Health of the Czech Republic</td>
</tr>
<tr>
<td>Denmark</td>
<td>Innovation Fund Denmark</td>
</tr>
<tr>
<td>EU</td>
<td>European Commission</td>
</tr>
<tr>
<td>Estonia</td>
<td>Ministry of Social Affairs</td>
</tr>
<tr>
<td>Finland</td>
<td>Suomen Akatemia (Academy of Finland)</td>
</tr>
<tr>
<td>France</td>
<td>French National Research Agency Agence Nationale de la Recherche</td>
</tr>
<tr>
<td>France</td>
<td>Ministry of Higher Education and Research</td>
</tr>
<tr>
<td>Germany</td>
<td>Federal Ministry of Education and Research</td>
</tr>
<tr>
<td>Germany</td>
<td>Federal Ministry of Health</td>
</tr>
<tr>
<td>Hungary</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>Ireland</td>
<td>Health Research Board</td>
</tr>
<tr>
<td>Israel</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>Italy</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>Italy</td>
<td>Consiglio Nazionale delle Ricerche (National Research Council)</td>
</tr>
<tr>
<td>Lithuania</td>
<td>Research Council of Lithuania</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>Fonds national de la Recherche</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>Ministère de la Santé</td>
</tr>
<tr>
<td>Netherlands</td>
<td>The Netherlands Organisation for Health Research and Development</td>
</tr>
<tr>
<td>Norway</td>
<td>The South-Eastern Norway Regional Health Authority</td>
</tr>
<tr>
<td>Sweden</td>
<td>Swedish Research Council</td>
</tr>
<tr>
<td>Sweden</td>
<td>Vinnova</td>
</tr>
<tr>
<td>Spain</td>
<td>The National Institute of Health Carlos III</td>
</tr>
<tr>
<td>Spain (Region)</td>
<td>Ministry for Health - Basque Government</td>
</tr>
<tr>
<td>Slovenia</td>
<td>Ministry of Education, Science and Sport</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Medical Research Council</td>
</tr>
</tbody>
</table>
The Regional Foundation for Biomedical Research has not adopted yet an intellectual property policy to regulate its relation with the beneficiaries of the granted projects.

Nevertheless we encourage them to follow the best practices for what concerns the Intellectual Property Management.
INITIATION PHASE

IP CONSIDERATIONS

INITIATION
- NDA
- MoU
- Internal Policy
- Innovation Manager

Planning
- Identify Background
- Define access rights
- Define the consortium IP Policy
- Estimate the activities
- Assign Resources
- Define the deliverable

Ownership of the results
Joint Ownership
INITIATION PHASE

IP CONSIDERATIONS

EXECUTION
- DETECT IP
- PUBLICATION PRE-REVIEW
- DISSEMINATION PRE-REVIEW
- VALUE CONSIDERATION
- VALUE STRATEGY

Monitoring and Control
- PROTECT IP
- COMPETITORS MONITORING
- DEFEND
- REVIEW STRATEGY
INITIATION PHASE

IP CONSIDERATIONS

- CLOSING
  - EXPLOITATION
  - AGREEMENTS
  - DEFEND
  - LICENSING
  - SPIN-OFF
  - SPIN OUT
### LOMBARDY TECHNOLOGICAL CLUSTERS

<table>
<thead>
<tr>
<th>Area tecnologica</th>
<th>Nome CTL</th>
<th>Acronimo CTL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aerospazio</td>
<td>Lombardia Aerospace Cluster</td>
<td>LAC</td>
</tr>
<tr>
<td>Fabbrica intelligente</td>
<td>Associazione Fabbrica Intelligente Lombardia</td>
<td>AFIL</td>
</tr>
<tr>
<td>Agrifood</td>
<td>Cluster Alta Tecnologia Agrifood Lombardia</td>
<td>CAT.AL</td>
</tr>
<tr>
<td>Mobilità</td>
<td>Associazione Cluster Lombardo della Mobilità</td>
<td>CLM</td>
</tr>
<tr>
<td>Energia</td>
<td>Lombardy Energy Cleantech Cluster</td>
<td>LE2C</td>
</tr>
<tr>
<td>Chimica verde</td>
<td>Lombardy Green Chemistry Association</td>
<td>LGCA</td>
</tr>
<tr>
<td>Scienze della vita</td>
<td>Cluster Lombardo Scienze della Vita</td>
<td>LLS</td>
</tr>
<tr>
<td>Tecnologie per ambienti di vita</td>
<td>Fondazione cluster regionale lombardo delle Tecnologie per gli Ambienti di Vita</td>
<td>TAV</td>
</tr>
<tr>
<td>Tecnologie per smart communities</td>
<td>Fondazione Cluster Tecnologie per le Smart Cities &amp; Communities - Lombardia</td>
<td>SCC</td>
</tr>
</tbody>
</table>
THE EXPERIENCE OF OUR TECHNOLOGICAL CLUSTERS

MAIN GOALS:

• Support CNAO Center with the establishment of an internal assessment process which facilitates the valorisation and market exploitation research projects.

• Elaborate a database of standard documents which can be adopted in all the phases of the IP management process.

• Build the right expertise to carry out continuous research scouting activities.

• Support the assessment of research outcomes against the market demand and the best IP strategy.
Realisation of e-learning platform dedicated to the protection of the intellectual property and technology transfer in the Life Science sector containing videos of experts.
The Lombardy cluster for Living Environments has facilitated, aslo from the IPRs point of view the following activities:

- **Framework agreement between CNR ITIA, CNR IBFM, CNR IENI (National Research Council) and Lombardy Region:** Thanks to the Cluster, as main binding organisation among dseveral research players in Lombardy, thare has been established a permanent dialogue between different National Research Council institutes whai has eventually led to a framework programme and the initiation of two projects: RIPRENDÒ@home and FHfFC: Future Home for Future Communities.

- **Collaboration contracts:** Furthermore TAV cluster has promoted and facilitated collaborations between Industry and academy, such as the collaboration between Ab medica and Univerlecco, or Politecnico Milano and CNR. Again with Ab medica group within the national project “DESIGN FOR ALL” - integration and advanced Human Machine Interfaces in design for Ambient Assisted Living – the Cluster TAV was responsible for the dissemination activities, in line with the IP managament process that has been established in order to not jeopardise potential IP likely to be generated.
LOMBARDY FOUNDATION FOR BIOMEDICAL RESEARCH

Fondazione Regionale per la Ricerca Biomedica

**Headquarter**: piazza Città di Lombardia 1, 20124 Milano

**Operating Office**: via T. Taramelli 12, 20124 Milano

**Phone**: +39 02.6765.0166-0170

**Website**: [www.frrb.regione.lombardia.it](http://www.frrb.regione.lombardia.it)

**E**: gianni.derrico@frrb.it